Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. (Q44605265)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

author name string

Stephan Wagner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Michaela Schmitz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Andrea Bedynek

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Ulrich Keller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Thomas Demant

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

Journal of Lipid Research

19 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

174-185

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy

19 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

HDL metabolism in hypertriglyceridemic states: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

Mechanism of action of gemfibrozil on lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M300309-JLR200

10.1194/JLR.M300309-JLR200

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14523053%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference